Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
beige.party is one of the many independent Mastodon servers you can use to participate in the fediverse.
A home to friendly weirdos. The Grey Gardens of the Fediverse (but beige). Occasionally graphically cacographic. Definitely probably not a cult (though you'll never be 100% sure). Beige-bless 🙏

Administered by:

Server stats:

447
active users

beige.party: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.6

#diabetes

23 posts19 participants1 post today
Public *
Max Leibman

Continuous glucose monitoring is kind of a miracle, but one of the shortcomings of the one I use (FreeStyle Libre) that I find irksome: a precipitous decline in blood sugar will cause the sensor to go offline. It’s always, always a sharp decline, but never for a spike.

Glucose shooting up because you’ve been irresponsible? Nope, we saw that. It’s in your permanent record.

Glucose coming down fast because you’re doing something good for yourself? We’re gonna take a break. You don’t need that accomplishment in your graph, do you?

#diabetes#motivation#QuantifiedSelf
Public
COD

The Medtronic CGM sensors will probably double in price from $100 each to $200 each due to the Republican Tariffs. Most diabetics using them use 5 or 6 a month. So $500-$600 to $1000 to $1200 a month. And that is before you buy infusion sets and insulin.

Are we great again yet?

#diabetes#healthcare#tariffs
Public
BedastGPT

I did a small experiment this morning.

Since I can now set temporary basal rates with CIQ, when I woke up, before getting out of bed (I often just lay for a bit), I set a 150% basal rate for half an hour. I was above target anyway.

It seems to have blunted my typical FOTF!

I suspect this is how my body would prepare for a cortisol spike, normally.

#Diabetes#Tandem#Mobi
Public *
Bill Taroli :neurodiversity:

FFS So Abbott’s Libre 3 app, for continuous glucose monitoring, allows itself to be installed on a variety of devices and iOS versions. But should you have issues with it they point you at a doc saying it’s not supported on all devices and OS versions. So be on an insecure OS release (18.0!) or we don’t support you. FAIL

When might they get around to upgrading and fixing their app? No ETA. Critical alerts, DENIED!

#Abbott#FreeStyleLibre3#Libre3
Public *
Chris Geoghooligan

I contacted my #endocrinologist about potentially using #fiasp in my #Tandem #tslim #insulinpump to help mitigate the issues I have balancing bolus response times & unpredictable #gastroparesis occurrence & duration. She’s not outright opposed which is nice, but she mentioned a different pump that is supposed to approximate how a pancreas works: #BetaBionics. I hadn’t heard of it. Does anyone have experience with this pump?

betabionics.com

Beta BionicsMakers of the first and only fully automated bionic pancreasThe iLet Bionic Pancreas is improving lives of people living with type 1 diabetes by helping to reduce data and decision-making overload.
#T1D#Type1Diabetes#Diabetes
Public
Jan R. Boehnke

Protocol for one of our current trials published:

DIAMONDS evaluates a #diabetes #SelfManagement intervention for people living with severe mental illness
bmjopen.bmj.com/content/15/3/e

Registration incl. SAP at ISRCTN22275538
isrctn.com/ISRCTN22275538

BMJ Open · DIAMONDS—a diabetes self-management intervention for people with severe mental illness: protocol for an individually randomised controlled multicentre trialIntroduction Type 2 diabetes mellitus (T2DM) is two to three times more common in people with severe mental illness (SMI) than in the general population. Supporting self-management in diabetes is fundamental to improving clinical outcomes. The DIAMONDS trial aims to evaluate the clinical and cost effectiveness of a novel, codesigned, supported diabetes self-management programme for people with T2DM and SMI. Methods and analysis This multicentre, two-armed, parallel, individually randomised controlled trial will be conducted in National Health Service mental health trusts across England. We will recruit 380 participants (≥18 years old) with a diagnosis of SMI (schizophrenia, bipolar disorder, schizoaffective disorder, psychosis and severe depression) and T2DM. Eligible and consenting participants will be randomised to the DIAMONDS intervention or treatment as usual. The intervention group will receive one-to-one sessions with a trained DIAMONDS Coach for six months. These sessions will focus on goal setting, action planning and diabetes self-management education, supported by a paper-based workbook and an optional digital application. Individuals allocated to the control group will continue to receive usual care and may be offered National Institute for Health and Care Excellence-recommended generic diabetes self-management education programmes in line with usual practice. The primary outcome is the difference in glycated haemoglobin (HbA1c) between both groups at 12 months postrandomisation. The secondary outcomes include measures of physical and mental health, diabetes complications and physical activity. Economic and process evaluations will also be performed. Outcomes will be collected at baseline and at six and 12 month post-randomisation. Ethics and dissemination This study received ethics approval by the West of Scotland Research Ethics Committee 3 (22/WS/0117). Findings will be published in peer-reviewed, academic and professional journals. We will also be producing plain language summaries, infographics and audio summaries on the website, as well as attending conferences and dissemination events. A summary of the results will be distributed to all participants and other relevant stakeholders, and we will use social media channels, websites and knowledge exchange events to communicate our findings beyond academic audiences. Trial registration number [ISRCTN22275538][1]. [1]: /external-ref?link_type=ISRCTN&access_num=ISRCTN22275538
#SMI#Multimorbidity#ISRCTN
ExploreLive feeds
About